{"entity":{"id":"nct07063745","kind":"trial","name":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","aka":["MountainTAP-29"],"tldr":"A phase 2/3 trial testing Navlimetostat in non-small-cell lung cancer, now recruiting.","summary":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion is a phase 2/3 interventional study registered as NCT07063745, led by Bristol-Myers Squibb, and recruiting on the registry. Official title: A Randomised Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion. Planned enrolment is 590 participants (estimated). The study started in 2026-01-02 and primary completion is expected in 2031-08-12. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07063745","url":"https://clinicaltrials.gov/study/NCT07063745"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["navlimetostat"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07063745","phase":"2/3","setting":"A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT07063745","source":"https://clinicaltrials.gov/study/NCT07063745","fetchedAt":"2026-10-07T16:55:23.338Z","studySha256":"e7078d467b140c3e207269dbcf1b3e8ade0f2c40c28ef20e50db63583a61af9c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-23","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":590,"enrolmentType":"ESTIMATED","siteCount":321,"recruitingSiteCount":181,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Poland","Romania","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2026-01-02","startedType":"actual","enrolled":590,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07063745/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"navlimetostat","kind":"drug","name":"Navlimetostat","route":"/drugs/navlimetostat/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}